Auckland, New Zealand
Auckland, New Zealand

Time filter

Source Type

The invention relates to a genetically engineered bacterium comprising an energy-generating fermentation pathway and methods related thereto. In particular, the invention provides a bacterium comprising a phosphate butyryltransferase (Ptb) and a butyrate kinase (Buk) (Ptb-Buk) that act on non-native substrates to produce a wide variety of products and intermediates. In certain embodiments, the invention relates to the introduction of Ptb-Buk into a C1-fixing microoorgansim capable of producing products from a gaseous substrate.


A process for producing and controlling pyruvate derived products during the fermentation of a CO containing substrate by an acetogenic carboxydotrophic microorganism has been developed. The process involves increasing the concentration of at least one nutrient selected from the group consisting of vitamin B1, vitamin B5, vitamin B7 and mixtures thereof above the cellular requirement of the microorganism. When the concentration is increased, the production of 2,3-butanediol (2,3-BDO) increases whereas the production of the other metabolites is virtually unchanged. The effect is reversible so that when the concentration is decreased, the production of 2,3-BDO is also decreased. This allows one to control the ratio of ethanol: 2,3-BDO to a desired value which can vary from 4:1 to 1:2.


The invention provides methods for improving efficiency of fermentation by arginine supplementation, and genetically modified bacterium for use therefor. More particularly the invention provides methods for (i) increasing the production ATP intensive products with arginine supplementation, (ii) increasing utilization of arginine by a C1-fixing bacterium; and (iii) providing C1-fixing bacterium with optimized arginine de-aminase pathways.


Patent
Lanzatech | Date: 2017-03-08

Processes, as well as associated systems and computer program (software) products, are disclosed for the biological conversion of CO into desired end products such as ethanol. The control methodologies used for these processes can advantageously result in a reduced time required for a batch operation or other initial operating period, prior to achieving a continuous operation, which may be demarcated either by the addition of fresh culture medium at a defined flow rate or by another process initiation target. The control methodologies may alternatively, or in combination, improve a process performance parameter, such as productivity of the desired end product or bacterial growth rate, during this batch operation or other initial operating period.


Patent
Lanzatech | Date: 2016-12-21

The invention provides genetically engineered microorganisms with modified hydrogenase activity and methods related thereto. Typically, the microorganisms are C1-fixing microorganisms with one or more disruptive mutations in a hydrogenase enzyme or a hydrogenase accessory enzyme. The microorganisms may have improved tolerance to toxins, such as acetylene, isocyanide, ammonium, or nitric oxide, improved production of products, such as ethanol, 2,3-butanediol, and isopropanol, and/or improved fixation of carbon, such as carbon derived from CO or CO_(2).


Patent
Lanzatech | Date: 2017-05-17

Processes, as well as associated systems and computer program (software) products, are disclosed for the biological conversion of CO into desired end products such as ethanol. The control methodologies used for these processes can advantageously result in a reduced time required for a batch operat 5 ion or other initial operating period, prior to achieving a continuous operation, which may be demarcated either by the addition of fresh culture medium at a defined flow rate or by another process initiation target. The control methodologies may alternatively, or in combination, improve a process performance parameter, such as productivity of the desired end product or bacterial growth rate, during 10 this batch operation or other initial operating period.


Grant
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ENERGY.2013.3.2.1 | Award Amount: 55.61M | Year: 2015

Swedish Biofuels AB, as the co-ordinator of a broad ranging international consortium, proposes the construction of a pre-commerical demonstration plant for the production of fully synthetic paraffinic jet fuel from wood and other biomass. The consortium is to design, construct, commission and operate the plant, which will take a variety of raw materials and produce jet fuel that is compatible, without blending, with in-service and envisaged jet engines for both military and civilian applications. The plant capacity is 10,000 t/y of fuel, of which 5,000 t/y fully synthetic paraffinic jet fuel, the rest is diesel and aviation gasoline. The plant is based on technology that has been developed by Swedish Biofuels and LanzaTech, which. has been validated by the United States Air Force (USAF) and the United States Federal Aviation Authority (FAA). The technology has been granted patent protection in Europe the USA and the other major markets of the world. The plant, in the main, uses standard equipment. The non-standard equipment, roughly 10 % of the total, is to be manufactured by AS Remeksi Keskus. The plant is to be constructed in Sweden on a site owned by Perstorp Bioproducts AB, the wood raw materials to be supplied by SCA Energy AB. The fuel will be used by Deutsche Lufthansa AG for flight tests. When the fuel is available it will used by Saab as part of a Sweden national study involving the Swedish jet fighter Gripen. All products from the plant, jet fuel, diesel and aviation gasoline will be marketed by SkyEnergy BV. The raw material base for the demonstration plant will be extended during the project by 1) the introduction of ethanol produced from municipal solid waste by Abengoa Bioenergia Nuevas Tecnologias SA 2) the use of biogas for the production of syngas by Perstorp. This will improve the plant economics and environmental impact, as will be investigated by E4Tech SARL during the project.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: LCE-12-2014 | Award Amount: 14.56M | Year: 2015

The proposed STEELANOL project is based on producing bioethanol via an innovative gas fermentation process using exhaust gases emitted by the steel industry. The proposal addresses the specific topic Demonstrating advanced biofuel technologies (LCE-12 2014), under the call for competitive low-carbon energy in Horizon2020. The BF/BOF gaseous emissions are an unavoidable residue from the steelmaking process and are currently used for electricity production or being flared. Nevertheless, they can be advantageously used to produce bioethanol, thereby reducing the usage of fossil fuel molecules and thus significantly reducing GHG emissions. The bio-ethanol production would have a GHG impact that is over 65% lower compared to oil derived fuels STEELANOLs main objective is to demonstrate the cost-effective production of sustainable bioethanol, with the purpose of assessing the valorisation of this ethanol biofuel as a fuel derivative for the transport sector. A demonstration plant of approximately 25,000 tons/ethanol per year will be built; the first of its kind in Europe, and the largest facility built to date utilizing this technology globally. ArcelorMittal is the lead partner of this project and proposal. The gas fermentation technology will be supplied by LanzaTech, the engineering work will be performed by Primetals, and E4Tech will develop the Life Cycle Assessment of the produced fuels. Several key players in the transport sector, Boeing, Virgin Atlantic, Mitsui, have expressed their strong interest and support for the project.


Patent
Lanzatech | Date: 2016-07-08

The invention provides recombinant microorganisms and methods for the production of acetone from gaseous substrates. For example, the recombinant microorganism may be modified to express an exogenous thiolase, an exogenous CoA transferase, and an exogenous decarboxylase.


The invention provides genetically engineered microorganisms and methods for producing chorismate-derived products, such as para-hydroxybenzoic acid, salicylate, 2-aminobenzoate, 2,3-dihydroxybenzoate, and 4-hydroxycyclohexane carboxylic acid. Typically, the microorganism comprises at least one of (a) an exogenous chorismate pyruvate lyase, (b) an exogenous isochorismate synthase, (c) an exogenous isochorismate pyruvate lyase, and (d) a prephenate synthase comprising a disruptive mutation.

Loading Lanzatech collaborators
Loading Lanzatech collaborators